How Does Ilevro Work? Mechanism of Action Explained in Plain English

Ilevro (nepafenac 0.3%) is not just another NSAID eye drop — it works in a uniquely clever way that sets it apart from ketorolac, diclofenac, and other ophthalmic anti-inflammatories. Understanding how Ilevro works helps explain why it only needs to be used once a day and why it's considered effective for post-cataract surgery inflammation.

What Is Inflammation After Cataract Surgery?

During cataract surgery, the eye's lens is broken apart with ultrasound energy (phacoemulsification) and removed, then replaced with an artificial intraocular lens. This process, however gentle and routine, is still a physical disruption to eye tissue — and the body responds with inflammation.

The key drivers of this inflammatory response are molecules called prostaglandins. When tissue is damaged, an enzyme called cyclooxygenase (COX) converts arachidonic acid into prostaglandins. Prostaglandins cause blood vessels to dilate and become leaky, resulting in redness, swelling, and pain — exactly what you want to prevent in your newly-operated eye.

How Does Nepafenac (Ilevro) Work?

Here's where Ilevro's mechanism becomes interesting. Nepafenac itself — the molecule in the bottle — is not directly active. It's what pharmacologists call a prodrug: a compound that requires conversion inside the body to become its active form.

The conversion process works as follows:

You apply Ilevro to the surface of your eye.

Nepafenac penetrates the cornea — the clear front window of the eye — very rapidly (faster than ketorolac and diclofenac).

Once inside the eye, enzymes called hydrolases convert nepafenac into amfenac, the active anti-inflammatory compound.

Amfenac inhibits COX-1 and COX-2 — the enzymes that produce prostaglandins — blocking the inflammatory cascade.

By converting inside the eye rather than on the eye's surface, amfenac reaches the tissues where it's needed most (the iris, ciliary body, and retina) at higher concentrations than drugs that are applied in already-active form. This is why nepafenac was designed as a prodrug.

Why Can Ilevro Be Taken Just Once a Day?

The 0.3% concentration in Ilevro (three times the concentration of Nevanac's 0.1% formula) was specifically developed to achieve once-daily dosing. Research demonstrated that a single 0.3% dose delivered the same therapeutic concentration of amfenac inside the eye as the three daily doses of the 0.1% formulation. The result is equivalent anti-inflammatory coverage with dramatically simpler patient compliance.

Studies show peak amfenac concentrations in the eye are reached at a median of 0.75 hours (45 minutes) after applying Ilevro. Importantly, amfenac concentrations remain at therapeutic levels long enough to provide anti-inflammatory coverage through the 24-hour dosing interval.

Why Does Ilevro Start Before Surgery?

The pre-surgical dosing (beginning 1 day before cataract surgery, with an additional dose 30-120 minutes pre-operatively) is clinically important. Pre-loading the eye with COX inhibition before the surgical insult begins pre-emptively suppresses the inflammatory response that would otherwise be triggered the moment the surgeon makes their incision.

This pre-emptive approach also helps prevent intraoperative miosis — the pupil constriction that can occur during cataract surgery as a result of prostaglandin release. A larger, stable pupil makes the surgical procedure technically easier and safer.

How Does Ilevro Compare to Other Ophthalmic NSAIDs?

All ophthalmic NSAIDs share the core mechanism: COX inhibition and prostaglandin reduction. What varies is how they get to the target tissue, how long they last, and how much they affect COX-1 vs COX-2:

Nepafenac (Ilevro/Nevanac): Prodrug; rapid corneal penetration; active form (amfenac) inhibits both COX-1 and COX-2; reaches deeper tissues

Bromfenac (Prolensa/BromSite): Active molecule; lipophilic structure for corneal penetration; particularly potent COX-2 inhibitor; 3.7× more potent than diclofenac for COX-2

Ketorolac (Acular): Active molecule; well-established long-term safety data; non-selective COX inhibitor; achieves measurable systemic levels

Diclofenac: Active molecule; COX inhibitor; older formulation with longer track record; QID dosing

Why the Prodrug Design Matters for Safety

Because nepafenac is inactive at the corneal surface, it spends less time as an active compound in direct contact with the epithelium. This means minimal contact time with the corneal surface as an active NSAID — potentially reducing the risk of surface toxicity that's associated with older, active-form ophthalmic NSAIDs. Studies have shown nepafenac penetrates the cornea 6 times faster than diclofenac in vitro, minimizing surface exposure time.

Want to know more about how to use Ilevro and what to expect? Read our comprehensive guide: What Is Ilevro? Uses, Dosage, and What You Need to Know in 2026.